PDF(1187 KB)
Diagnosis，treatment and gene mutation analysis in children with holocarboxylase synthetas deficiency
WANG Tong, YE Jun, HAN Lian-Shu, QIU Wen-Juan, ZHANG Hui-Wen, ZHANG Ya-Fen, GAO Xiao-Lan, WANG Yu, GU Xue-Fan
Chinese Journal of Contemporary Pediatrics ›› 2009, Vol. 11 ›› Issue (08) : 609-612.
PDF(1187 KB)
PDF(1187 KB)
Diagnosis，treatment and gene mutation analysis in children with holocarboxylase synthetas deficiency
OBJECTIVE: To report the clinical diagnosis, treatment and follow-up of children with holocarboxylase synthetas(HCS) deficiency and explore the gene mutation spectrum of the disease. METHODS: Eleven children with HCS deficiency were enrolled. Mass spectrometry analysis and biotinidase activity determination were used for diagnosis of HCS deficiency. HCS gene mutations were analyzed by PCR directed sequencing methods. Ten patients received oral biotin treatment (10-40 mg/d). Clinical effects of biotin treatment were observed. RESULTS: All 11 cases developed apathetic, lethargy and metabolic acidosis at different degrees, and 10 cases presented with skin lesions. The average blood 3-hydroxyisovaleryl-carnitine concentrations and urinary 3-methylcrontonylglycine and methylcitrate concentrations increased significantly. The biotinidase activity increased, being higher over 30% of the normal reference value. Four mutations in HCS gene were identified, and they were c.1522C>T (R508W), c.1088T>A (V363D), c.126G>T (E42D) and c.1994G>C (R665P) (a new variant) and the frequency was 50%, 29%, 7% and 14% respectively. The symptoms disappeared in 10 cases 1-2 weeks after biotin treatment, and blood and urinary abnormal metabolites were gradually reduced to normal 2-6 months after treatment. CONCLUSIONS: HCS deficiency is characterized by nervous system damage, skin lesions and metabolic acidosis. Mass spectrometry analysis, biotinidase activity determination and gene mutation analysis may be helpful in the definite diagnosis of this disorder. The effect of early biotin treatment is satisfactory. The mutations R508W and V363D might be hot-spots in Chinese children with HCS deficiency.［Chin J Contemp Pediatr, 2009, 11 (8):609-612］
Holocarboxylase-synthetas / Biotinidase / Tandem mass spectrometry / Gas chromatography/ mass spectrometry / Gene / Child
［1］张春花. 先天性代谢异常的预防诊断与治疗［J］.中国当代儿科杂志，2005，7(5):477-480.
［2］谢利娟，朱建幸，朱晓东，李华军，韩连书，顾学范. 经高危筛查发现的遗传性代谢病15例分析［J］.中国当代儿科杂志，2008，10(1):31-34.
［3］Han LS, Ye J, Qiu WJ, Gao XL, Wang Y, Gu XF. Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: a fouryear report［J］.J Inherit Metab Dis, 2007, 30(4):507-514.
［4］韩连书，高晓岚，叶军,邱文娟，顾学范. 串联质谱分析干血滤纸片酰基肉碱方法的建立［J］.中华检验医学杂志, 2005, 28(1):88-91.
［5］宋金青，杨艳玲，孙芳，张月华，包新华，钱宁，等.气相色谱质谱联用分析在有机酸尿症筛查与诊断中的应用［J］.中国医刊, 2006, 41(2):38-40.
［6］宋元宗，方素珍，封志纯，王自能. 尿素酶预处理-气相色谱-质谱法在多种羧化酶缺陷病诊断治疗中的应用［J］.中国当代儿科杂志，2004，6(2):128-130.
［7］Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y. Mutations in the holocarboxylase synthetase gene HLCS ［J］.Hum mutat, 2005, 26(4):285-290.
［8］Wolf B. Disorders of biotin metabolism［M］. //Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular basis of inherited disease.8th ed.New York:McGraw Hill, 2001, 3935-3962.
［9］邹丽萍，王旭. 疑难病研究—生物素酶缺乏症［J］.中国当代儿科杂志，2005，7(5) :435-438.
［10］Morrone A, Malvagia S, Donati MA, Funghini S, Ciani F, Pela I, et al. Clinical findings and biochemical and molecular analysis of four patients with holocarboxylase synthetase deficiency［J］. Am J Med Genet, 2002, 111(1):10-18.
［11］叶军，韩连书，邱文娟，张惠文，高晓岚，王瑜，等. 联合质谱技术在多种羧化酶缺陷病诊治中的应用［J］.中国实用儿科杂志, 2008, 23(8):582-585.
［12］Santer R, Muhle H, Suormala T, Baumgartner ER, Duran M, Yang X, et al. Partial response to biotin therapy in a patient with holocarboxylase synthetase deficiency: clinical, biochemical, and molecular genetic aspects［J］. Mol Genet Metab, 2003, 79(3):160-166.
［13］Dupuis L, Campeau E, Leclerc D, Gravel RA. Mechanism of biotin responsiveness in biotin-responsive multiple carboxylase deficiency［J］. Mol Genet Metab, 1999, 66(2):80-90.
